THL Taps Ex-WTW CEO Guilmette to Lead Healthcare Deals

Thomas H. Lee Partners, the Boston private equity firm with $45 billion under management, just made the kind of hire that telegraphs where it's hunting next. Dave Guilmette — the former CEO of Willis Towers Watson's Health and Benefits division and one-time president of OneDigital — is joining as Executive Partner focused on healthcare and employee benefits. It's not a board seat or advisory role. This is operational.

The appointment, announced April 14, positions THL to lean harder into a sector that's both massive and maddeningly fragmented: the $1.4 trillion employee benefits consulting and administration market. Guilmette spent four decades inside it, most recently running WTW's benefits arm before stepping down in 2024. Before that, he built OneDigital from regional player to national force as president, a tenure that coincided with the firm's own aggressive roll-up strategy backed by Abry Partners.

THL's move arrives as consolidation in benefits brokerages and healthcare services accelerates. The firm already owns stakes in population health platforms, pharmacy benefit managers, and care delivery networks. Adding someone who's negotiated employer health plans for Fortune 500 companies — and who understands the operational guts of benefits administration — suggests THL isn't just investing in the sector. It's preparing to reshape it.

Guilmette will work across THL's investment team to source deals, provide due diligence on healthcare services targets, and guide portfolio companies post-acquisition. In private equity parlance, that means he's there to tell operating teams what actually works when you're trying to integrate three benefits brokerages or scale a care navigation platform across state lines. Theory meets the messy reality of ERISA compliance and legacy IT systems.

Employee benefits consulting sits at the intersection of two forces private equity loves: recurring revenue and fragmentation. According to IBISWorld, the benefits brokerage industry alone generates over $30 billion annually in the U.S., split across thousands of firms. The top 10 players control less than 40% of the market. That's a roll-up waiting to happen.

But it's not a simple buy-and-flip game. Benefits consulting is sticky — client relationships span decades, and switching costs are real — but integration is brutal. You're stitching together commission structures, broker networks, technology stacks, and compliance frameworks that vary state by state. Firms that get it wrong end up with revenue churn and broker attrition. Firms that get it right build durable, high-margin platforms that throw off cash.

Guilmette's background suggests THL wants to be in the latter camp. At WTW, he oversaw a division serving 33,000 clients globally, managing health and benefits programs for employers representing 80 million people. That scale brings credibility when you're pitching a $500 million benefits platform to a CIO who's skeptical of private equity's operational chops.

His OneDigital tenure is equally telling. The firm pursued an aggressive buy-and-build strategy under Abry's ownership, completing dozens of acquisitions to become one of the largest privately held insurance brokerages in the country. Guilmette helped steer that expansion as president, meaning he's seen firsthand what works when you're integrating 10 agencies a year and trying to maintain service quality.

This isn't THL's first rodeo in healthcare services. The firm has a long track record in the sector, including investments in ambulatory care, healthcare IT, and specialty pharmacy. Recent bets include Confluent Health, a physical therapy platform, and stakes in behavioral health and diagnostic services businesses.

But the employee benefits angle is different. It sits upstream of care delivery — employers are the ones writing the checks, and benefits brokers influence which networks, pharmacy managers, and wellness platforms get into those contracts. Controlling that layer means access to deal flow, data on utilization trends, and the ability to steer employer spending toward THL portfolio companies. It's strategic, not just financial.

Guilmette's appointment suggests THL sees a chance to connect those dots. If you own a pharmacy benefit manager and a benefits consulting platform, you can cross-sell. If you own a care navigation tool and a brokerage that advises 10,000 employer clients, you've got built-in distribution. The synergies are real — assuming you can execute.

The question is whether THL can move fast enough. Competition for healthcare services assets is fierce. Rival PE firms, strategics like UnitedHealth and CVS, and well-capitalized growth equity players are all circling the same deals. Guilmette's Rolodex might be the edge THL needs to get calls before the broader auction process starts.

The table above shows just a slice of recent activity. Sedgwick, for instance, operates in third-party administration for benefits and claims — adjacent to where Guilmette's expertise lies. Accolade is a care navigation platform that sits inside employer benefits programs. The deals are piling up because the sector is capital-intensive, regulatory complexity creates barriers, and scale matters.

The Executive Partner title sounds ceremonial. It's not. At firms like THL, these roles function as internal consultants, deal scouts, and credibility validators rolled into one. Guilmette will likely spend half his time on sourcing — taking calls from bankers, attending industry conferences, sitting down with founders who aren't formally selling yet but might be convinced.

If THL leans into benefits brokerage roll-ups, Guilmette's playbook is well-tested. Start with a strong platform — ideally one with national reach, a modern tech stack, and a recognized brand. Bolt on regional and specialty brokerages that add geographic density or vertical expertise (think healthcare, higher ed, nonprofits). Standardize back-office functions. Invest in technology to automate renewals and compliance. Keep top brokers happy with earnouts and equity.

OneDigital executed this model relentlessly under Abry's ownership. So did AssuredPartners, Hub International, and BroadStreet Partners. The risk is that you overpay for mediocre assets, lose key producers post-close, or discover that the acquired firm's book of business is smaller or less sticky than diligence suggested. Guilmette has seen those failures up close.

His WTW experience adds a different dimension. That firm operates at enterprise scale, serving multinational corporations with complex global benefits programs. If THL wants to move upmarket — competing for larger, more sophisticated targets — Guilmette knows how those deals get structured, what buyers care about, and where the operational landmines sit.

He also understands the regulatory environment, which matters more than ever. The Consolidated Appropriations Act, transparency rules around prescription drug pricing, and state-level surprise billing laws have all added compliance layers to benefits administration. Firms that can't keep up face litigation risk and client attrition. Guilmette's tenure at WTW coincided with many of these regulatory shifts, so he's navigated them at scale.

And then there's the technology question. Benefits administration is undergoing a slow-motion digitization — employee self-service portals, AI-driven plan recommendations, integrated wellness platforms. Legacy brokerages that haven't invested in tech are getting left behind. Guilmette will likely push THL portfolio companies to modernize faster, using WTW's playbook as a reference point.

Employer health spending keeps climbing — now exceeding $13,000 per employee annually on average, according to the Kaiser Family Foundation. That's pushing companies to rethink benefits strategies, exploring everything from direct contracting with health systems to on-site clinics to carve-out pharmacy deals. The firms that advise on those decisions wield enormous influence.

At the same time, the line between broker, consultant, and technology vendor is blurring. Brokerages are launching proprietary benefits platforms. Tech companies are offering brokerage services. Traditional consultants are buying care delivery assets. Guilmette's cross-sector experience positions him to help THL navigate that convergence — and potentially drive it.

THL isn't the only PE firm circling employee benefits. Genstar, Abry, KKR, and TPG have all made bets in adjacent spaces. UnitedHealth's Optum division is buying everything it can in primary care, specialty pharmacy, and care management. CVS is doing the same through Aetna and its recent acquisitions. The strategics have deeper pockets and can offer synergies that pure financial buyers can't match.

Where THL can compete is speed, operational focus, and sector expertise. Strategics move slowly, burdened by integration challenges from prior acquisitions. Pure financial buyers without healthcare chops struggle to underwrite complex regulatory and reimbursement risk. THL, with Guilmette in-house, can theoretically move faster and underwrite smarter.

But the multiples are high. Middle-market benefits brokerages routinely trade at 10-15x EBITDA, sometimes higher for firms with strong growth or niche positioning. At those valuations, returns depend on operational improvements and multiple arbitrage — buying smaller firms at lower multiples, integrating them into a platform, and exiting the combined entity at a higher valuation. It's a proven playbook, but it requires flawless execution.

Guilmette's track record suggests he knows where the pitfalls are. But knowing and avoiding are two different things, especially when you're under pressure to deploy capital and every decent asset has three other bidders circling.

The clearest signal of THL's intentions will come in the next 12-18 months. If the firm announces a platform acquisition in benefits brokerage or population health — especially one with Guilmette quoted prominently in the press release — you'll know this wasn't a symbolic hire. If THL starts selectively adding smaller bolt-ons to existing portfolio companies in adjacent sectors, that's a sign Guilmette is running a more surgical strategy.

Also worth tracking: whether Guilmette surfaces publicly at industry conferences or speaking engagements. Executive Partners often serve as the firm's public face in a given sector, building relationships and signaling investment appetite. If he's suddenly keynoting HCEG events or sitting on panels at NAHU, that's market positioning.

WTW gives Guilmette credibility. But OneDigital gives him the roll-up scars — the real ones. Running a benefits division inside a global consulting giant is one thing. Integrating 30 acquisitions over five years while maintaining service levels, keeping brokers from walking, and hitting growth targets? That's the job THL actually needs done.

OneDigital's rise under Abry's ownership wasn't smooth. There were integration stumbles, broker defections, and client losses along the way. But the firm ultimately reached scale, becoming one of the 10 largest employee benefits brokerages in the U.S. Guilmette was there for the messiest parts. That's the knowledge base THL is buying.

His WTW experience adds enterprise-level sophistication — understanding how large self-insured employers think, how global benefits programs get structured, what matters in RFP processes. But the OneDigital chapter is where he learned how to build a platform from acquired parts. That's the skill set that translates directly to PE-backed growth strategies.

It's also worth noting what Guilmette's resume doesn't have: a failed exit or a portfolio company bankruptcy. In healthcare services PE, that's rarer than it should be. Plenty of executives have led roll-ups that looked great on paper but imploded under leverage or failed to hit exit valuations. Guilmette's track record is clean. That matters when you're trying to close deals and the seller is choosing between four term sheets.

Hiring a big name is great until it isn't. Executive Partners can become expensive figureheads if the firm doesn't deploy capital in their sector quickly. Guilmette's value decays if THL doesn't close a major healthcare services deal within the next 12-18 months. His relationships go stale. His market knowledge gets dated. And the firm eats the cost of a senior hire who's not generating returns.

There's also the risk that Guilmette's experience doesn't map cleanly onto THL's investment thesis. WTW and OneDigital both operated in mature, established markets. If THL is hunting earlier-stage healthcare tech or care delivery models that haven't proven unit economics, Guilmette's playbook might not apply. Benefits brokerage roll-ups are a known commodity. Telehealth platforms or AI-driven care navigation tools are a different game.

The table captures what keeps THL partners up at night. Multiples are the biggest headwind. You can't pay 14x EBITDA, layer on leverage, and expect a 3x return unless you're adding serious operational value or getting multiple expansion on exit. Guilmette's job is to make sure the first part happens.

Broker retention is the other landmine. In benefits brokerages, the producers are the asset. If they walk after the deal closes, you've bought a hollowed-out client list and a CRM system. Keeping them requires more than earnouts — it requires culture, autonomy, and a clear growth path. Guilmette's leadership style and industry reputation will matter here.

THL has always been sector-focused. The firm organizes around industry verticals — healthcare, financial services, business services, technology — and builds deep expertise in each. Hiring someone like Guilmette fits that model. According to THL's website, the firm has invested in over 160 companies since inception, with healthcare representing a substantial portion of that activity.

But the Executive Partner model also reflects a broader shift in PE. Firms are competing less on capital and more on operational value-add. The ability to source proprietary deals, provide hands-on portfolio support, and derisk complex integrations — that's what differentiates returns now. Guilmette is a tool in that toolkit.

It's also a signal that THL sees healthcare services, and benefits specifically, as a multi-year theme. You don't hire an Executive Partner for a single deal. You hire them because you think the next five years will produce 10+ investment opportunities in that domain. The fragmentation, regulatory complexity, and capital intensity of employee benefits all suggest THL is right.

Whether they can execute — whether Guilmette can turn his Rolodex and experience into actual returns — is the open question. But the setup is compelling. The market is ripe. The firm has capital. And they just hired someone who's built this exact playbook before.

Now comes the hard part: actually doing it.